Peptides
Peptides are short chains of amino acid linked by peptide bonds, typically defined as containing between 2 and 50 residues, distinguishing them from larger polypeptides and proteins.
Peptides are short chains of amino acid linked by peptide bonds, typically defined as containing between 2 and 50 residues, distinguishing them from larger polypeptides and proteins. As fundamental biological molecules, peptides participate in virtually every physiological process: they function as hormones, neurotransmitters, Signaling molecules, antimicrobial agents, and structural components. Their relatively small size compared to full proteins confers key pharmacological advantages, including improved tissue penetration, lower immunogenicity, and the capacity to engage challenging molecular targets such as protein–protein interaction interfaces that are inaccessible to small-molecule drugs. Peptides are biosynthesized through ribosomal translation or non-ribosomal enzymatic pathways, and can also be generated through the hydrolysis of larger proteins by proteases, a process central to both digestion and the production of bioactive food-derived peptides.
From a therapeutic standpoint, peptides occupy a privileged position at the interface of small molecules and biologics. Their modular amino acid sequences can be rationally engineered to confer high specificity for receptor binding, enzyme inhibition, or immune modulation. Advances in solid-phase peptide synthesis, recombinant expression, and, more recently, artificial intelligence-guided design have dramatically expanded the accessible sequence and structural space for therapeutic peptide discovery. These attributes have made peptides central targets and tools across dermatology, oncology, nanomedicine, and food science.
Where the papers sit
10 papers from the last 6 months study peptides directly · updated from PubMed 5 Nov 2026
Study type 0 clinical trials · 5 human data · 4 preclinical · 1 unclassified
Themes 3 themes · 1 new direction
-
Peptide-Protein Interaction Design
Structure-guided computation is converging with experimental validation to create peptide inhibitors for diverse protein interactions. Targets include p53-COP1 ubiquitination, HPV host-pathogen interfaces, Factor Xa and ACE, with screening, binding affinities and molecular dynamics used to prioritize candidates. Synthetic intrinsically disordered proteins add a focus on temperature-triggered morphology rather than inhibition. The common direction is mechanistic, quantitatively benchmarked peptide design, although target diversity prevents a single therapeutic strategy.
5 papers · 50%
-
Peptide Immunogenicity and Delivery
Lipid nanoparticles and complex coacervates are being optimized to control peptide delivery, immunogenicity and stability. HPV peptide antigens with manganese adjuvant illustrate codelivery for cancer immunotherapy, while TCR-pMHC models seek to predict antigen-specific recognition. Polypeptide sequence effects on virus thermostability show that formulation behavior depends on molecular design. The field is moving toward predictive, multifunctional formulations, but links between computed specificity, physical stability and clinical immune responses remain open.
3 papers · 30%
-
Peptide Structure and Function
Chemical editing and structure-guided design are expanding control over peptide structure and function. Silver(I)-mediated amide-to-ester conversion enables modification of unprotected peptides for protein synthesis and engineering. Stapled peptides instead tune oligomeric-state recognition of lactate dehydrogenase, linking conformation to metabolic targeting. Therapeutic benefit remains an early design-stage question.
2 papers · 20%
Polypeptide coacervates use peptides as vaccine-stabilizing excipients rather than therapeutic agents or antigens
The porcine parvovirus vaccine model uses poly(lysine)- and poly(glutamate)-based polypeptide coacervates to protect an intact virus from thermal degradation, with peptide length and sequence determining thermostability 42734273Sep. Whereas the other papers use peptides as drugs, antigens, inhibitors, synthesis substrates, or engineered self-assembling materials, this study assigns them a formulation role: preserving vaccine infectivity under severe heat exposure. That expands the role of peptides from biologically active or structural components to protective excipients for vaccine storage and transport.
Papers
The 10 papers from the last 6 months that study peptides directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Peptide-Protein Interaction Design (5)
- A dual-functional antiviral and anticancer peptide to target intricate host-pathogen interacting proteins of human papillomavirus associated with head and neck cancer. PloS one · 9 Oct 2026 PMID 42853814
- Temperature-Triggered Nanoscale Morphological Transitions in a Synthetic Intrinsically Disordered Protein. Biomacromolecules · 14 Sept 2026 PMID 42734274
- Discovery and mechanistic benchmarking of ACE inhibitory Di- and tripeptides. Bioorganic chemistry · 29 Aug 2026 PMID 42667758
- Computational design and evaluation of Factor Xa inhibitory peptides derived from the Tamarind Kunitz inhibitor reactive loop. Biochemical and biophysical research communications · 22 Jul 2026 PMID 42485797
- Computational design and experimental validation of peptide inhibitors targeting the p53-COP1 interaction to suppress p53 ubiquitination. Bioorganic chemistry · 3 Jul 2026 PMID 42398393
Peptide Immunogenicity and Delivery (3)
- Phenolic Hydroxyl-Containing Lipid Nanoparticles Enable Codelivery of HPV Peptide Antigens and Manganese Adjuvant for Cancer Immunotherapy. ACS applied bio materials · 28 Oct 2026 PMID 42947624
- Polypeptide Sequence Effects on Virus Thermostability in Complex Coacervate Formulations. Biomacromolecules · 14 Sept 2026 PMID 42734273
- Predicting specificity of TCR-pMHC interactions using machine-learning and biophysical models. Cell systems · 13 Aug 2026 PMID 42594866
Peptide Structure and Function (2)
- Silver(I)-mediated amide-to-ester transformation on unprotected peptides for protein chemical synthesis and engineering. Science advances · 30 Sept 2026 PMID 42814821
- Structure-based design of stapled peptides targeting the oligomeric state of lactate dehydrogenase. European journal of medicinal chemistry · 15 Jul 2026 PMID 42456470
By study type
Human data, design not indexed (5)
- A dual-functional antiviral and anticancer peptide to target intricate host-pathogen interacting proteins of human papillomavirus associated with head and neck cancer. PloS one · 9 Oct 2026 PMID 42853814
- Discovery and mechanistic benchmarking of ACE inhibitory Di- and tripeptides. Bioorganic chemistry · 29 Aug 2026 PMID 42667758
- Predicting specificity of TCR-pMHC interactions using machine-learning and biophysical models. Cell systems · 13 Aug 2026 PMID 42594866
- Computational design and evaluation of Factor Xa inhibitory peptides derived from the Tamarind Kunitz inhibitor reactive loop. Biochemical and biophysical research communications · 22 Jul 2026 PMID 42485797
- Computational design and experimental validation of peptide inhibitors targeting the p53-COP1 interaction to suppress p53 ubiquitination. Bioorganic chemistry · 3 Jul 2026 PMID 42398393
Preclinical: animal, cell and lab studies (4)
- Silver(I)-mediated amide-to-ester transformation on unprotected peptides for protein chemical synthesis and engineering. Science advances · 30 Sept 2026 PMID 42814821
- Temperature-Triggered Nanoscale Morphological Transitions in a Synthetic Intrinsically Disordered Protein. Biomacromolecules · 14 Sept 2026 PMID 42734274
- Polypeptide Sequence Effects on Virus Thermostability in Complex Coacervate Formulations. Biomacromolecules · 14 Sept 2026 PMID 42734273
- Structure-based design of stapled peptides targeting the oligomeric state of lactate dehydrogenase. European journal of medicinal chemistry · 15 Jul 2026 PMID 42456470
Unclassified: not yet indexed with MeSH (1)
- Phenolic Hydroxyl-Containing Lipid Nanoparticles Enable Codelivery of HPV Peptide Antigens and Manganese Adjuvant for Cancer Immunotherapy. ACS applied bio materials · 28 Oct 2026 PMID 42947624
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-07-29 by GPT. Drafted by language models from published abstracts; not medical advice.